ERGOMED

News

Guildford, UK, May 7th, 2014

Rolf Stahel joins Board of Ergomed as Non-Executive Chairman

Guildford, UK – 7th May 2014: Ergomed, a UK-based drug development services company, today announces the appointment of Rolf Stahel to its Board as Non-Executive Chairman.

Rolf Stahel brings over 30 years’ experience in the global pharmaceutical industry. He led Shire Pharmaceuticals Group plc as Chief Executive Officer from March 1994…


London, UK, Feb 3, 2014

ERGOMED Group enters codevelopment deal with Ferrer

UK, London, 3 February 2014 – ERGOMED Group, a leading clinical development company working with biotechnology and pharmaceutical companies today announces that it has entered into an agreement with Ferrer, a privately-held Spanish pharmaceutical company, to support further clinical studies of Lorediplon in patients with insomnia. Ferrer also announced it is collaborating…


London, UK, Apr 24, 2013

ERGOMED Group and CEL-SCI Sign Co-Development Agreement for Multikine in Head and Neck Cancer

Ergomed Clinical Research Ltd. (“ERGOMED Group ”) today announced the signing of a co-development and revenue sharing agreement with CEL-SCI Corporation  (NYSE MKT: CVM) for Multikine in head and neck cancer. Under the agreement ERGOMED Group will work with CEL-SCI conducting a multicenter, multinational, randomized Phase 3 trial with Multikine in head and neck…


London, UK, April 10, 2013

Aeterna Zentaris and ERGOMED Group Sign Co-Development and Profit Sharing Agreement for AEZS-108 in Endometrial Cancer

Ergomed Clinical Research Ltd. (“ERGOMED Group”) today announced the signing of a co-development and profit sharing agreement with Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”) for AEZS-108 in endometrial cancer. ERGOMED Group was selected as the contract clinical development organization to conduct the multicenter, multinational, randomized Phase 3 trial with AEZS-108 in…


London and Cambrige, UK, March 23, 2013

ERGOMED Group Announces Recruitment of Phase II trial in diabetic neuropathic pain has completed and study is expected to report later in mid-2012

Avlar Bioventures and Excalibur Fund Managers, the UK based life science venture capital groups and ERGOMED Group, an international provider of drug development services announced today that the planned recruitment of 120 patients has completed on schedule in the Phase II study with Oral BVT.115959 – a novel A2A agonist in diabetic neuropathic pain. Avlar…


Page 18 of 19« First...10...1516171819
Translate »